Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 5, 1997, Pages 497-502

  Michalides, Rob J A M ^a   Van Veelen, Nicoletta M J ^a   Kristel, Petra M P ^a   Hart, Augustinus A M ^a   Loftus, Barbara M ^a   Hilgers, Frans J M ^a   Balm, Alfons J M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0030919581     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900050045005     Document Type: Article

References (25)

1. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20:187-190.
2. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene, 1992;7:355-361.
3. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995;55:949-956.
4. Michalides RJ, van Veelen N, Hart A, Loftus B, Wientiens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995;55:975-978.
5. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res. 1992;52:2980-2983.
6. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994;54:3107-3110.
7. Zwijsen R, Klompmaker R, Wientjens E, Kristel P, Van der Burg B, Michalides R. Cyclin D1 triggers autonomous growth of breast cancer cells by governing the cell cycle exit. Mol Cell Biol. 1996;16:2554-2560.
8. Schuuring E, Verhoeven E, van Tinteren H, et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992;52:5229-5234.
9. Parise O Jr, Janot F, Guerry R, et al. Chromosome 11 q13 gene amplifications in head and neck squamous cell carcinomas: relation with lymph node invasion. Int J Oncol. 1994;5:309-313.
10. Muller D, Millon R, Lidereau R, et al. Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas, Eur J Cancer B Oral Oncol. 1994;30:113-120.
11. Meredith SD, Levine PA, Burns JA, et al. Chromosome 11p13 amplification in head and neck squamous cell carcinoma: association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995;121:790.
12. Mak-Kregar S, Baris G, Lebesque JV, Balm AJM, Hart AA, Hilgers FJM. Radiotherapy of tonsillar and base of the tongue carcinoma: prediction of local control. Eur J Cancer B Oral Oncol. 1993;29:119-125.
13. Mak-Kregar S, Keus RB, Balm AJM, Hilgers FJM. Carcinoma of the soft palate and the posterior oropharyngeal wall. Clin Otolaryngol. 1994;19:22-27.
14. Elias MM, Hilgers FJM, Keus RB, Gregor T, Hart AA, Balm AJM. Carcinoma of the pyriform sinus: a retrospective analysis of treatment over a 20 year period. Clin Otolaryngol. 1995;20:249-253.
15. Gregor RT, Oei SS, Baris G, Keus RB, Balm AJM, Hilgers FJM. Supraglottic laryngectomy with postoperative radiation versus primary radiation in the management of supraglottic laryngeal cancer. Am J Otolaryngol. 1996;17:1-7.
16. Beahrs OH, Henson DE, Hutter RVP, Myers MH (American Joint Committee on Cancer), eds. Manual for Staging of Cancer. 3rd ed. Philadelphia, Pa: JB Lippincott; 1988.
17. Michalides R, Hageman PH, van Tinteren H, et al. A clinico-pathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 1996;73:728-734.
18. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-1327.
19. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;B34:187-220.
20. Wright P. Adjusted P-values for simultaneous interference. Biometrics. 1992; 48:1005-1013.
21. Kaplan EL, Meier P. Regression models and life-tables. J R Stat Soc. 1972; 438:187-220.
22. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184-194.
23. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994;74:152-158.
24. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome: frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 1995;10:1217-1227.
25. Boyle JO, Hakim J, Koch W, van der Riet P, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993; 53:4477-4480.